Institutional shares held 147 Million
84.2K calls
55.5K puts
Total value of holdings $246M
$140K calls
$92K puts
Market Cap $296M
177,090,000 Shares Out.
Institutional ownership 83.25%
# of Institutions 156


Latest Institutional Activity in CERS

Top Purchases

Q3 2024
Silvercrest Asset Management Group LLC Shares Held: 3.52M ($5.87M)
Q3 2024
Citadel Advisors LLC Shares Held: 1.06M ($1.77M)
Q3 2024
Morgan Stanley Shares Held: 2.93M ($4.89M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 1.38M ($2.3M)
Q3 2024
Acadian Asset Management LLC Shares Held: 518K ($865K)

Top Sells

Q3 2024
Ark Investment Management LLC Shares Held: 18.2M ($30.4M)
Q3 2024
Senvest Management, LLC Shares Held: 6.01M ($10M)
Q3 2024
Gsa Capital Partners LLP Shares Held: 960K ($1.6M)
Q3 2024
Nikko Asset Management Americas, Inc. Shares Held: 7.04M ($11.8M)
Q3 2024
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 7.04M ($11.8M)

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.


Insider Transactions at CERS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
2.09M Shares
From 28 Insiders
Grant, award, or other acquisition 1.88M shares
Open market or private purchase 37K shares
Exercise of conversion of derivative security 173K shares
Sell / Disposition
491K Shares
From 7 Insiders
Open market or private sale 491K shares

Track Institutional and Insider Activities on CERS

Follow CERUS CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CERS shares.

Notify only if

Insider Trading

Get notified when an Cerus Corp insider buys or sells CERS shares.

Notify only if

News

Receive news related to CERUS CORP

Track Activities on CERS